Masterflex Achieves 2025 Forecast with Record Earnings and Strengthened Financial Position

According to preliminary figures, Masterflex SE has achieved its forecast for the 2025 financial year and posted new record earnings. The Management Board had forecast revenue of EUR 100 million to EUR 105 million and EBIT of EUR 12 million to EUR 15 million for the full year 2025. Consolidated revenue rose to EUR 102.6 million, exceeding the previous year's level of EUR 98.1 million by 4.6%. The operational performance developed positively despite a continuing challenging economic environment.

The US subgroup performed particularly well in 2025. The medical technology area also experienced dynamic demand growth. As a result, the share of high-margin medical technology in consolidated revenue increased from 18% in 2024 to 21% in the 2025 financial year. Despite the economic headwinds, which were particularly noticeable in Germany, demand in the industrial customer sectors grouped under “Tech” and in the trading business declined only moderately. At EUR 19.8 million, the order backlog remained stable at the end of the year and was thus in line with the previous year's level.

Masterflex once again achieved record results. Masterflex recorded a 7.4% increase in operating EBITDA to EUR 19.5 million, while operating EBIT was up 9.8% on the previous year's figure of EUR 12.7 million to EUR 14.0 million, also marking a new record. Despite the impact of currency losses and start-up costs for the new site in Morocco, this resulted in a further increase in the operating EBIT margin in the 2025 financial year to 13.6% compared with 13.0% in the previous year. At EUR 13.7 million, EBIT was within the forecast range. The Masterflex Group is thus demonstrating sustained earnings strength.

Masterflex also further strengthened its financial position. The equity ratio increased to 73.3%. At the same time, financial liabilities were significantly reduced. Net debt fell to EUR 2.7 million after EUR 9.0 million in the previous year. The debt ratio thus improved significantly once again to 0.1. Dr Andreas Bastin, CEO of Masterflex SE, comments: “Despite a continuing challenging economic environment, we met our forecasts in the 2025 financial year, achieved solid revenue growth and slightly increased our profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing.”

The figures are still subject to confirmation by the auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and the 2026 forecast will be published on 31 March 2026. Additional information about the company is available at https://www.crossalliance.de and the original release can be viewed at https://www.newmediawire.com.